Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction
(World News USA)

Contribution To Literature: The PARAGON-HF trial failed to show that sacubitril-valsartan reduced adverse events among patients with HFpEF. Description: The goal of the trial was to evaluate the neprilysin-angiotension receptor inhibitor sacubitril-valsartan among patients with heart failure with preserved ejection fraction (HFpEF). Study Design Randomized Parallel Blinded Patients with HFpEF were randomized to sacubitril-valsartan 97/103 mg twice daily (n = 2,419) versus valsartan 160 mg twice daily (n = 2,403). Total number of enrollees: 4,822 Duration of follow-up: 35 months Mean patient age: 73 years Percentage female: 52% Percentage with diabetes: 44% Inclusion criteria: Patients...